Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06218589 · ClinicalTrials.gov registry record · NA

Non-Invasive Diagnostic Tests for MASLD in Pediatric Population

A NA study of Non-Alcoholic Fatty Liver Disease (NAFLD) and Metabolic Dysfunction Associated Steatotic Liver Disease, sponsored by Emory University.

Recruiting
Registry status
NA
Development phase
200
Enrollment target
2
Study locations

NCT06218589: Recruiting NA study of Non-Alcoholic Fatty Liver Disease (NAFLD) and Metabolic Dysfunction Associated Steatotic Liver Disease, sponsored by Emory University.

NCT06218589 is a NA study of Non-Alcoholic Fatty Liver Disease (NAFLD) and Metabolic Dysfunction Associated Steatotic Liver Disease that is actively recruiting participants, run by Emory University. The registered enrollment target is 200 participants, above the 69-participant average among 9 other Non-Alcoholic Fatty Liver Disease (NAFLD) trials with a reported enrollment target (190% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06218589, a NA study of Non-Alcoholic Fatty Liver Disease (NAFLD) and Metabolic Dysfunction Associated Steatotic Liver Disease, is actively recruiting participants, sponsored by Emory University.

RECRUITING
Registry status
NA
Development phase
200 participants
Enrollment target
2
Study locations

Study Summary

This study aims to test the utility of Velacur ultrasound as a non-invasive, rapid, point of care diagnostic tool for detecting the presence and amount of hepatic steatosis in children and adolescents aged 2 - 20 years.

Primary Outcome

The performance of Velacur is assessed as the percentage of correctly identified cases of MASLD (true positives) detected by Velacur imaging. The presence of MASLD will be compared with the determinations from MRI and liver biopsy, the current gold standards.

Interventions

  • DIAGNOSTIC_TEST MRI
  • DIAGNOSTIC_TEST Velacur
  • DIAGNOSTIC_TEST Blood sample collection for biomarkers
  • DIAGNOSTIC_TEST Liver biopsy

Study Locations (2)

Georgia

  • Children's Healthcare of Atlanta (CHOA) - Atlanta
  • Emory Children's Center - Atlanta

Trial Details

FieldValue
Enrollment Target 200 participants
Start Date 2024-01-18
Est. Completion 2026-01-31
Phase NA
Emory University

1,208 total trials

What NCT06218589 shows while recruiting

NCT06218589 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, above the 69-participant average among 9 other Non-Alcoholic Fatty Liver Disease (NAFLD) trials with a reported enrollment target (190% higher).

The record links to 2 conditions, with Non-Alcoholic Fatty Liver Disease (NAFLD) appearing as the primary indexed condition, and to 4 interventions - of which MRI is the first listed.

NCT06218589 reports a single indexed study location in Georgia.

Frequently Asked Questions

What is clinical trial NCT06218589 about?

NCT06218589 is a clinical study titled "Non-Invasive Diagnostic Tests for MASLD in Pediatric Population". This study aims to test the utility of Velacur ultrasound as a non-invasive, rapid, point of care diagnostic tool for detecting the presence and amount of hepatic steatosis in children and adolescents aged 2 - 20 years.

What is the current status of trial NCT06218589?

This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2024-01-18. Estimated completion is 2026-01-31.

What conditions does trial NCT06218589 study?

This clinical trial studies the following conditions: Non-Alcoholic Fatty Liver Disease (NAFLD), Metabolic Dysfunction Associated Steatotic Liver Disease.

What interventions are being tested in trial NCT06218589?

The interventions under investigation include: MRI (DIAGNOSTIC_TEST), Velacur (DIAGNOSTIC_TEST), Blood sample collection for biomarkers (DIAGNOSTIC_TEST), Liver biopsy (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT06218589?

This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06218589 being conducted?

This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Non-Alcoholic Fatty Liver Disease (NAFLD)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06218589's enrollment target sits among peer trials

200 2nd of 9 the highest of 9 other Non-Alcoholic Fatty Liver Disease (NAFLD) trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Non-Alcoholic Fatty Liver Disease (NAFLD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00107289 · 200 participants · Phase 2

    Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

  • NCT00109174 · 200 participants · NA

    MRS Measurement of Glutamate and GABA Metabolism in Brain

  • NCT00177268 · 200 participants

    Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research

  • NCT00493688 · 200 participants

    A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06218589, the US trial registry maintained by the National Library of Medicine. NCT06218589 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.